# CRISPR Delivery Methods: A Comprehensive Guide for Students ## Introduction to CRISPR Delivery ### What is CRISPR Delivery? CRISPR delivery refers to the set of techniques used to introduce the components of the CRISPR-Cas9 system into target cells. The CRISPR-Cas9 system, derived from the bacterial adaptive immune system, consists of two core elements: the Cas9 endonuclease and a guide RNA (gRNA) that directs Cas9 to a specific DNA sequence. For genome editing to occur, both components must reach the nucleus of a living cell. The process of getting them there—across the plasma membrane, through the cytoplasm, and into the nucleus—is the essence of CRISPR delivery. The delivery problem is not trivial. The plasma membrane is a hydrophobic barrier designed to keep foreign material out. Cas9 protein is approximately 160 kDa, and the gRNA is a negatively charged nucleic acid polymer. Neither crosses the membrane spontaneously. Furthermore, once inside the cell, the components must avoid degradation by nucleases and proteases, evade immune recognition, and localize to the nucleus where genomic DNA resides. The choice of delivery method determines not only whether editing occurs but also how efficiently, how specifically, and with what collateral damage. ### Why Delivery Matters in Genome Editing Delivery is the rate-limiting step in most CRISPR experiments. You can design the perfect guide RNA with in silico tools, but if the delivery method fails, no editing occurs. Conversely, a poorly designed guide delivered efficiently will produce editing—but with potentially unacceptable off-target effects. The delivery method influences three critical parameters: editing efficiency (the fraction of cells with the desired modification), cell viability (the fraction of cells that survive the delivery process), and specificity (the ratio of on-target to off-target edits). Different experimental goals demand different delivery approaches. A researcher performing a [CRISPR Knockout](/knowledge/molecular-biology/crispr-knockout) screen in immortalized cancer cells may tolerate some cytotoxicity because millions of cells are available. A clinician delivering a therapeutic edit to a patient's hepatocytes has no such luxury—every cell counts, and immune responses are a serious concern. Understanding the delivery landscape is therefore essential for designing any CRISPR experiment, whether in a dish or in a living organism. ## Viral Vectors for CRISPR Delivery Viruses are natural gene delivery vehicles. Over millions of years, they have evolved sophisticated mechanisms to enter cells, evade immune detection, and deliver their genetic cargo to the nucleus. Researchers have repurposed these mechanisms by replacing viral genes with CRISPR components, creating recombinant viral vectors. Three viral systems dominate the field: adeno-associated viruses (AAVs), lentiviruses, and adenoviruses. ### Adeno-Associated Virus (AAV) Vectors AAV is a small (approximately 25 nm), non-enveloped parvovirus that requires a helper virus (adenovirus or herpesvirus) for replication. In the absence of a helper virus, AAV establishes a latent infection by integrating into a specific site on human chromosome 19 (AAVS1) or, more commonly, persists as episomal concatemers. Recombinant AAV (rAAV) vectors retain the viral capsid but remove all viral coding sequences, leaving only the inverted terminal repeats (ITRs) required for packaging. This makes rAAV non-pathogenic and unable to replicate. The AAV capsid determines its tropism—which cell types it infects. There are over a dozen naturally occurring serotypes, each with distinct preferences. AAV2 was the first to be characterized and is the most studied. AAV8 and AAV9 efficiently transduce liver and muscle, respectively. AAV9 can cross the blood-brain barrier, making it valuable for central nervous system targeting. Capsid engineering has produced variants like AAV-PHP.eB with enhanced brain penetration in mice. The major limitation of AAV is its packaging capacity. The AAV genome is approximately 4.7 kb, and the ITRs occupy about 300 bp, leaving roughly 4.4 kb for cargo. The *Streptococcus pyogenes* Cas9 (SpCas9) coding sequence alone is 4.2 kb, leaving almost no room for a guide RNA expression cassette, let alone a promoter or regulatory elements. This has driven the search for smaller Cas9 orthologs. *Staphylococcus aureus* Cas9 (SaCas9) is 3.2 kb, and when paired with a compact promoter, it fits within the AAV capacity. Alternatively, dual-AAV systems split Cas9 into two halves, each packaged in a separate AAV particle, with reconstitution occurring via intein-mediated protein splicing or split-intron recombination. AAV vectors are the most commonly used viral vectors for in vivo CRISPR delivery due to their low immunogenicity and long-term expression. However, sustained Cas9 expression increases the risk of off-target editing and can trigger a cytotoxic T-cell response against Cas9-expressing cells. This has motivated the development of self-inactivating AAV systems and the use of cell-specific promoters to restrict expression. ### Lentiviral Vectors Lentiviruses, a genus of retroviruses that includes HIV-1, integrate their genetic material into the host genome. Recombinant lentiviral vectors are produced by co-transfecting packaging cells with three plasmids: one encoding the viral structural proteins (gag-pol), one encoding the envelope glycoprotein (usually vesicular stomatitis virus G protein, VSV-G, for broad tropism), and one containing the cargo flanked by long terminal repeats (LTRs). The resulting particles are pseudotyped, replication-incompetent viruses that can transduce both dividing and non-dividing cells. The key advantage of lentiviral vectors is their packaging capacity—up to 8–10 kb, sufficient for SpCas9 and a guide RNA expression cassette in a single vector. Integration into the host genome ensures stable, heritable expression, which is useful for generating stable cell lines and for [CRISPR Screening](/knowledge/molecular-biology/crispr-screening) applications where you need to track edited cells over many passages. The disadvantages are equally significant. Random integration carries the risk of insertional mutagenesis—disrupting [tumor suppressor genes](/knowledge/molecular-biology/tumor-suppressor-gene) or activating oncogenes. This makes lentiviral vectors less attractive for therapeutic applications. Additionally, sustained Cas9 expression from an integrated transgene increases off-target editing. For this reason, many researchers use lentiviral delivery for initial editing and then subclone cells to isolate edited clones, which can then be screened for loss of the transgene. Lentiviral vectors are the workhorse for pooled CRISPR knockout screens. A library of guide RNAs is packaged into lentiviral particles, and cells are transduced at a low multiplicity of infection (typically 0.3–0.5) to ensure that most cells receive at most one guide. After selection with puromycin or another antibiotic marker, the pool of edited cells is subjected to a selective pressure, and guide RNA abundance is quantified by next-generation sequencing. ### Adenoviral Vectors Adenoviruses are non-enveloped, double-stranded DNA viruses with a genome of approximately 36 kb. First-generation adenoviral vectors delete the E1 and E3 genes, creating space for up to 8 kb of foreign DNA. These vectors transduce a wide range of dividing and non-dividing cells and achieve high-level, transient transgene expression because the viral genome remains episomal. Adenoviral vectors are less commonly used for CRISPR delivery than AAV or lentivirus, but they have specific niches. Their large capacity allows delivery of SpCas9 and guide RNA in a single vector. They are particularly effective for transducing primary cells, including post-mitotic neurons, which are refractory to many non-viral methods. The main drawback is immunogenicity—adenoviral capsid proteins elicit strong innate and adaptive immune responses, limiting their use in vivo and causing cytotoxicity in some cell types. ## Non-Viral Delivery Methods Non-viral methods avoid the immunogenicity, insertional mutagenesis risk, and manufacturing complexity of viral vectors. They fall into two categories: physical methods that transiently disrupt the membrane and chemical methods that package CRISPR components into nanoparticles that cells take up. ### Electroporation and Microinjection Electroporation applies a brief, high-voltage electric field to cells, creating transient pores in the plasma membrane through which nucleic acids and proteins can enter. The technique is rapid, reproducible, and works with plasmid DNA, mRNA, and ribonucleoprotein (RNP) complexes. For cultured cells, electroporation is often the most efficient delivery method, achieving editing rates of 70–90% in easily transfectable lines like HEK293T. The protocol involves suspending cells in a conductive buffer containing the CRISPR components, placing the suspension in a cuvette between two electrodes, and applying an exponential decay or square-wave pulse. Typical parameters for mammalian cells are 100–300 V, 25–500 µF capacitance, and 1–10 ms pulse duration, though optimal settings vary by cell type. The electric field strength must be carefully titrated: too low, and the pores do not form; too high, and the cells die from irreversible membrane damage. Microinjection is the direct physical injection of CRISPR components into individual cells using a fine glass needle. It is labor-intensive and technically demanding, but it offers the highest precision and is the method of choice for generating transgenic animals. In mouse zygotes, microinjection of Cas9 protein complexed with guide RNA (an RNP) into the pronucleus achieves high editing efficiency with minimal off-target effects. The procedure requires a micromanipulator, an inverted microscope, and considerable skill. A skilled operator can inject 100–200 zygotes per hour. ### Lipid Nanoparticles (LNPs) Lipid nanoparticles are spherical vesicles composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipid conjugates. The ionizable lipid is the key component: at physiological pH, it is neutral, but in the acidic environment of the endosome, it becomes positively charged, facilitating endosomal escape. This pH-dependent behavior minimizes toxicity while enabling efficient cytosolic delivery. LNPs are the most clinically advanced non-viral delivery system, validated by their use in mRNA vaccines. For CRISPR delivery, LNPs can encapsulate mRNA encoding Cas9 and guide RNA, or Cas9 protein complexed with guide RNA (RNP). The manufacturing process involves microfluidic mixing: an ethanol solution of lipids is rapidly mixed with an aqueous solution of the cargo, driving self-assembly of nanoparticles with a size of 60–100 nm. The advantages of LNPs are substantial. They are non-integrating, so there is no risk of insertional mutagenesis. They can be administered systemically and will accumulate in the liver due to the natural tropism of LNPs for hepatocytes—a consequence of apolipoprotein E (ApoE) binding to the particle surface and subsequent uptake via the low-density lipoprotein receptor (LDLR). This makes LNPs ideal for liver-targeted therapies, such as the treatment of transthyretin amyloidosis or hereditary angioedema. The main limitation is that unmodified LNPs are not cell-type-specific; they deliver cargo primarily to the liver, and targeting other tissues requires surface modification with ligands or antibodies. ### Polymer-Based Delivery Cationic polymers, such as polyethyleneimine (PEI), poly-L-lysine (PLL), and chitosan, condense negatively charged nucleic acids into polyplexes via electrostatic interactions. PEI is the most widely used in research settings. It has a high density of amine groups that buffer the endosomal pH, causing osmotic swelling and endosomal rupture—the so-called "proton sponge" effect. Polymer-based delivery is inexpensive and simple: you mix the polymer with plasmid DNA or mRNA, incubate for 15–30 minutes at room temperature to allow complex formation, and add the mixture to cells. The N/P ratio (the ratio of polymer nitrogen groups to nucleic acid phosphate groups) is a critical parameter; a ratio of 5–10 is typical for PEI. However, polymer-based delivery is generally less efficient than electroporation or LNPs, and the polymers themselves are cytotoxic at high concentrations. The polyplexes are also less stable in serum, limiting their use in vivo. ## Delivery of Different CRISPR Forms The CRISPR system can be delivered in three molecular formats: plasmid DNA, mRNA, or ribonucleoprotein (RNP) complexes. The choice of format profoundly affects the kinetics, efficiency, and safety of editing. ### Plasmid DNA Delivery Plasmids are circular, double-stranded DNA molecules that encode both Cas9 and the guide RNA. They are the simplest and cheapest format to produce—standard molecular biology techniques suffice. Plasmids can be delivered by electroporation, lipofection, or polymer-based methods. The main advantage of plasmid delivery is that it provides a template for transcription, so the cell produces its own Cas9 and guide RNA. This allows for sustained expression over several days, which can increase editing efficiency. However, sustained expression also increases off-target editing and can trigger an innate immune response through the cGAS-STING pathway, which detects cytosolic DNA. Plasmid delivery is also limited by the need for the DNA to reach the nucleus for transcription. Non-dividing cells are poorly transfected with plasmids because the nuclear envelope remains intact. This is a significant limitation for in vivo applications where the target cells are post-mitotic. ### mRNA Delivery mRNA encoding Cas9 can be synthesized in vitro using bacteriophage RNA polymerases (T7, T3, or SP6) and modified nucleotides. The mRNA is typically capped at the 5' end and polyadenylated at the 3' end to enhance stability and translation. Guide RNA can be delivered separately as a synthetic RNA or co-encapsulated with the mRNA. mRNA delivery offers several advantages over plasmid DNA. It does not need to enter the nucleus—translation occurs in the cytoplasm—so it works in non-dividing cells. The expression is transient, lasting 24–72 hours, which reduces off-target editing. The mRNA is also degraded by endogenous nucleases, leaving no trace in the genome. The disadvantages include the cost and complexity of in vitro transcription, the inherent instability of RNA, and the potential for immune stimulation. Modified nucleosides, such as N1-methylpseudouridine, are used to reduce innate immune recognition by Toll-like receptors (TLRs) and RIG-I. ### Ribonucleoprotein (RNP) Delivery RNP delivery involves pre-assembling the Cas9 protein with the guide RNA in vitro, then delivering the complex directly to cells. This is the most direct approach—the cell receives the active editing machinery, and no transcription or translation is required. RNP delivery has several advantages. Editing begins immediately upon delivery, and the RNP is degraded within hours, minimizing off-target effects. The protein component can be modified with nuclear localization signals (NLS) to ensure efficient nuclear import. Because no DNA or RNA is delivered, the risk of genomic integration is zero, and immune stimulation is reduced. The main challenge is the production of recombinant Cas9 protein, which requires bacterial expression and purification. The RNP complex is also less stable than plasmid DNA and must be handled carefully to avoid degradation. Electroporation is the most common method for RNP delivery, achieving high efficiency in primary cells including T cells and hematopoietic stem cells. | Feature | Plasmid DNA | mRNA | RNP | |---|---|---|---| | Time to editing onset | 12–48 h (requires [transcription and translation](/knowledge/molecular-biology/transcription-translation)) | 4–12 h (requires translation) | Immediate | | Duration of Cas9 activity | Days (sustained expression) | 24–72 h (transient) | Hours (protein degradation) | | Off-target risk | High | Moderate | Low | | Nuclear entry required | Yes | No | No (NLS facilitates import) | | Cost | Low | Moderate | High | | Best for | Stable cell lines, screens | In vivo delivery, non-dividing cells | Primary cells, therapeutic ex vivo editing | ## Targeting Specific Tissues and Cells Delivering CRISPR components to the right cells is as important as delivering them at all. Systemic administration of a viral vector or nanoparticle will distribute the cargo throughout the body, potentially editing unintended tissues. Several strategies have been developed to achieve cell-type-specific delivery. ### Cell-Specific Promoters When using viral vectors, the promoter driving Cas9 expression can restrict editing to specific cell types. For example, the thyroxine-binding globulin (TBG) promoter restricts expression to hepatocytes, while the synapsin I (SYN1) promoter restricts expression to neurons. This approach works because the promoter is only active in cells that express the corresponding [transcription factors](/knowledge/molecular-biology/transcription-factor). The limitation is that promoter specificity is never absolute. Some promoters are "leaky," producing low levels of expression in off-target tissues. Additionally, this strategy only works for DNA-based delivery formats (plasmid or viral), not for mRNA or RNP. ### Ligand-Modified Nanoparticles Nanoparticles can be surface-modified with ligands that bind to receptors expressed on target cells. For example, LNPs decorated with N-acetylgalactosamine (GalNAc) bind to the asialoglycoprotein receptor (ASGPR) on hepatocytes, enhancing liver-specific uptake. Similarly, nanoparticles conjugated to anti-CD5 antibodies can target T cells, and those conjugated to transferrin can target cells expressing the transferrin receptor (TfR), which is upregulated in many cancers. The targeting ligand must be chosen carefully based on the expression profile of the target cell. The ligand-receptor interaction must be high-affinity and specific, and the receptor must internalize upon binding to facilitate endocytosis. ### In Vivo Delivery Challenges In vivo delivery faces additional barriers beyond those encountered in cell culture. The cargo must survive in the bloodstream, avoiding degradation by serum nucleases and clearance by the reticuloendothelial system (liver and spleen macrophages). The vascular endothelium must be crossed to reach parenchymal tissues. The blood-brain barrier prevents most delivery systems from reaching the central nervous system. Hydrodynamic injection is a physical method used in small animal models, particularly mice. A large volume of saline containing the CRISPR components (typically 10% of the body weight) is injected rapidly into the tail vein. The high pressure forces the solution into the liver, where the components are taken up by hepatocytes. This method is effective for liver editing but is too invasive for clinical use. ## Applications of CRISPR Delivery ### Gene Therapy for Genetic Diseases The most prominent application of CRISPR delivery is gene therapy. The first clinical trials using CRISPR-based therapies have targeted genetic diseases such as sickle cell disease and beta-thalassemia. In these trials, hematopoietic stem cells are harvested from the patient, edited ex vivo using electroporation to deliver Cas9 RNP targeting the BCL11A erythroid-specific enhancer, and then re-infused into the patient. The disruption of BCL11A reactivates fetal hemoglobin expression, compensating for the defective adult hemoglobin. In vivo gene therapy has also advanced. The approval of Casgevy (exagamglogene autotemcel) for sickle cell disease and beta-thalassemia represents a milestone for ex vivo CRISPR delivery. For in vivo delivery, LNPs targeting the liver have been used to edit the PCSK9 gene to lower cholesterol, and the TTR gene to treat transthyretin amyloidosis. These approaches are discussed in more detail in the context of [CRISPR in Medicine](/knowledge/molecular-biology/crispr-in-medicine). ### Engineering Crops and Livestock CRISPR delivery in plants typically uses *Agrobacterium tumefaciens*-mediated transformation or biolistic particle delivery (gene gun). In the former, the bacterium transfers a DNA segment (T-DNA) containing the CRISPR components into the plant cell genome. In the latter, gold or tungsten particles coated with plasmid DNA are physically shot into plant cells. Agricultural applications include improving yield, enhancing nutritional content, and conferring disease resistance. For example, CRISPR has been used to create powdery mildew-resistant wheat by disrupting the MLO gene, and to increase the oleic acid content of soybean oil by editing the FAD2 gene. In livestock, CRISPR has been used to produce pigs resistant to [porcine reproductive and respiratory syndrome](/knowledge/viruses/general/porcine-reproductive-and-respiratory-syndrome-genomic-surveillance-and-vaccine-strategies-using-bioinformatics) virus (PRRSV) by editing the CD163 receptor gene. ### [Functional Genomics](/blog/guides/functional-genomics) Screens Pooled CRISPR screens use lentiviral delivery to introduce a library of guide RNAs into a population of cells. Each cell receives a single guide, creating a population of cells with different gene knockouts. The population is then subjected to a selective pressure—a drug, a toxin, or a growth condition—and the guide RNAs that are enriched or depleted are identified by next-generation sequencing. This approach has identified genes essential for cancer cell proliferation, genes involved in drug resistance, and genes required for viral infection. The methodology is described in detail in the context of [CRISPR Screening](/knowledge/molecular-biology/crispr-screening). ## Methods to Study CRISPR Delivery Efficiency Quantifying delivery efficiency is essential for optimizing protocols and comparing methods. Several complementary approaches are used. ### Reporter Assays The simplest reporter assay uses a fluorescent protein. A plasmid encoding GFP can be co-delivered with the CRISPR components, and the fraction of GFP-positive cells can be measured by flow cytometry 24–48 hours after delivery. This measures transfection efficiency, not editing efficiency, but it is a useful proxy for optimizing delivery conditions. For editing-specific reporters, a GFP-based reporter system can be used. One common design involves a GFP gene that is disrupted by a stop codon and a frameshift. A guide RNA targeting the region adjacent to the stop codon is co-delivered with Cas9. If editing occurs, the frameshift is repaired, and GFP is expressed. The fraction of GFP-positive cells is a direct measure of editing efficiency. ### Genomic Analysis of Editing Outcomes The gold standard for measuring editing efficiency is next-generation sequencing (NGS) of the target locus. Genomic DNA is extracted from the edited cells, the target region is amplified by PCR, and the amplicons are sequenced. The frequency of insertions and deletions (indels) at the target site is calculated using bioinformatics tools such as CRISPResso2 or Tide. For a quick assessment, the T7 endonuclease I (T7EI) assay can be used. This assay detects mismatches in heteroduplex DNA formed when wild-type and edited alleles are hybridized. The PCR product is denatured and re-annealed, then digested with T7EI, which cleaves at mismatches. The digestion products are resolved by agarose gel electrophoresis, and the fraction of cleaved DNA is proportional to the editing efficiency. ### Protein and [RNA Quantification](/knowledge/diagnostics/molecular/rna-quantification-methods-spectrophotometry-fluorometry) Delivery of Cas9 protein can be confirmed by western blotting or immunofluorescence using anti-Cas9 antibodies. Guide RNA delivery can be confirmed by quantitative [reverse transcription PCR](/knowledge/diagnostics/molecular/reverse-transcription-pcr-principles-protocol-cdna-synthesis) (qRT-PCR) using primers spanning the guide sequence. These methods confirm that the components reached the cell but do not measure functional editing. ## Common Pitfalls and Troubleshooting ### Off-Target Effects Off-target editing is the unintended modification of genomic sites that share sequence homology with the guide RNA. The Cas9 nuclease tolerates mismatches, particularly in the distal region of the guide sequence (positions 12–20 from the PAM). Off-target effects can be minimized by using guide RNAs with high specificity scores, by using high-fidelity Cas9 variants (eSpCas9, SpCas9-HF1), and by limiting the duration of Cas9 activity through RNP or mRNA delivery. Students often make the mistake of assuming that a guide RNA with a perfect on-target match will have no off-targets. This is rarely true. Always perform a computational off-target prediction using tools like Cas-OFFinder or CRISPOR, and validate the top candidates experimentally. ### Cytotoxicity and Immune Response Delivery methods themselves can kill cells. Electroporation causes membrane damage; LNPs and polymers can be toxic at high concentrations; viral vectors can trigger innate immune responses. The immune response to Cas9 protein is a particular concern for therapeutic applications, as many humans have pre-existing antibodies against Cas9 from prior exposure to *S. aureus* or *S. pyogenes*. To minimize cytotoxicity, titrate the delivery conditions carefully. For electroporation, test a range of voltages and pulse durations. For LNPs, test a range of lipid-to-cargo ratios. Always include a mock-treated control to establish baseline viability. ### Choosing the Right Delivery Method There is no universal best delivery method. The choice depends on the cell type, the experimental goal, and the available resources. For a student starting a project, the following decision tree is useful: 1. Are you working with cultured cells? If yes, start with electroporation of RNP complexes—it is fast, efficient, and minimizes off-target effects. 2. Do you need stable expression for a long-term experiment? Use lentiviral delivery of a plasmid encoding Cas9 and guide RNA. 3. Are you working in vivo? Consider AAV for long-term expression or LNPs for transient, liver-targeted delivery. 4. Is your cell type difficult to transfect (primary cells, neurons, stem cells)? Use electroporation or lentiviral transduction. ## Frequently Asked Questions ### What are the main CRISPR delivery methods? The main methods are viral vectors (AAV, lentivirus, adenovirus), physical methods (electroporation, microinjection), and chemical methods (lipid nanoparticles, polymer-based delivery). Each has distinct advantages and limitations regarding efficiency, toxicity, and cargo capacity. ### How does CRISPR delivery work? CRISPR delivery works by overcoming the plasma membrane barrier to introduce Cas9 and guide RNA into cells. Viral vectors use natural infection mechanisms; electroporation creates transient membrane pores; nanoparticles are taken up by endocytosis and escape the endosome to reach the cytoplasm. ### What is the most efficient CRISPR delivery method? For cultured cells, electroporation of RNP complexes typically achieves the highest editing efficiency (70–90% in easily transfectable lines). For in vivo liver delivery, lipid nanoparticles are the most clinically advanced. The "most efficient" method depends on the context. ### What are the applications of CRISPR delivery? Applications include gene therapy for genetic diseases, engineering crops and livestock, [functional genomics](/blog/guides/functional-genomics) screens, creating disease models, and basic research into gene function. Delivery is the enabling technology for all of these applications. ### What are the challenges of CRISPR delivery? Challenges include delivering cargo to the correct cells, avoiding degradation in the bloodstream, minimizing off-target editing, reducing cytotoxicity, and avoiding immune responses. The packaging capacity of viral vectors and the lack of cell-type specificity in non-viral methods are additional hurdles. ### What is the difference between viral and non-viral CRISPR delivery? Viral vectors are efficient but immunogenic, have limited cargo capacity (AAV), and carry the risk of insertional mutagenesis (lentivirus). Non-viral methods are safer, cheaper, and more flexible but generally less efficient, particularly in vivo. ### How do I choose a CRISPR delivery method? Consider the cell type (dividing vs. non-dividing), the desired duration of Cas9 expression (transient vs. stable), the cargo format (plasmid, mRNA, or RNP), the experimental context (in vitro vs. in vivo), and the available resources. For most student projects, electroporation of RNP or lipofection of plasmid DNA is a reasonable starting point. ## Key Takeaways - CRISPR delivery is the critical bottleneck in genome editing; the choice of method determines efficiency, specificity, and cell viability. - Viral vectors (AAV, lentivirus, adenovirus) are efficient but have limitations in cargo capacity, immunogenicity, and safety. - Non-viral methods (electroporation, LNPs, polymers) are safer and more flexible but generally less efficient in vivo. - RNP delivery offers the fastest editing onset, lowest off-target risk, and no genomic integration, making it ideal for therapeutic ex vivo applications. - Cell-type-specific delivery can be achieved through promoters, surface ligands, or physical targeting strategies. - Delivery efficiency is measured using reporter assays, T7EI assays, and next-generation sequencing of the target locus. - The choice of delivery method should be guided by the experimental goal, the target cell type, and the cargo format, not by convention or convenience. ## Further Reading - Kazemian P et al. *Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components*. Molecular pharmaceutics. 2022. [PubMed 35594500](https://doi.org/10.1021/acs.molpharmaceut.1c00916) - Yang K et al. *Biogenic materials for CRISPR delivery and therapeutics*. Biomaterials science. 2023. [PubMed 36897609](https://doi.org/10.1039/d2bm02169b) - Berggreen AH et al. *CRISPR delivery with extracellular vesicles: Promises and challenges*. Journal of extracellular biology. 2023. [PubMed 38938376](https://doi.org/10.1002/jex2.111) - Demirci S et al. *Advances in CRISPR Delivery Methods: Perspectives and Challenges*. The CRISPR journal. 2022. [PubMed 36260301](https://doi.org/10.1089/crispr.2022.0051) - Tang H, Zhao X, Jiang X. *Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing*. Advanced drug delivery reviews. 2021. [PubMed 32147450](https://doi.org/10.1016/j.addr.2020.03.001) - Shin H, Kim J. *Nanoparticle-based non-viral CRISPR delivery for enhanced immunotherapy*. Chemical communications (Cambridge, England). 2022. [PubMed 35040444](https://doi.org/10.1039/d1cc05999h)
## Related Clinical & Scientific Guides * [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway) * [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor) * [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)